Provided by Tiger Trade Technology Pte. Ltd.

Summit Therapeutics PLC

15.93
+0.97006.48%
Volume:972.93K
Turnover:15.06M
Market Cap:12.28B
PE:-12.74
High:15.98
Open:14.85
Low:14.85
Close:14.96
52wk High:36.91
52wk Low:13.83
Shares:771.00M
Float Shares:129.00M
Volume Ratio:0.61
T/O Rate:0.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2507
EPS(LYR):-0.3100
ROE:-292.49%
ROA:-152.88%
PB:63.88
PE(LYR):-51.39

Loading ...

Summit Therapeutics (SMMT) Is Up 6.5% After FDA Accepts Ivonescimab BLA With 2026 PDUFA Date

Simply Wall St.
·
Feb 10

Assessing Summit Therapeutics (SMMT) Valuation After FDA Acceptance Of Ivonescimab BLA

Simply Wall St.
·
Feb 05

Summit Therapeutics Grants Stock Options to New Employees

Reuters
·
Jan 31

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jan 31

Analysts Offer Insights on Healthcare Companies: Talkspace (TALK), Ceribell, Inc. (CBLL) and Summit Therapeutics (SMMT)

TIPRANKS
·
Jan 30

Reassessing Summit Therapeutics (SMMT) After Sharp Pullback And DCF Upside Potential

Simply Wall St.
·
Jan 30

BUZZ-U.S. STOCKS ON THE MOVE-Blackstone, Summit, Lockheed Martin

Reuters
·
Jan 29

BUZZ-Summit rises after FDA accepts marketing application for lung cancer drug

Reuters
·
Jan 29

Summit Therapeutics Shares up 5.5% Premarket After US FDA Accepts Co's Application for Ivonescimab Approval

THOMSON REUTERS
·
Jan 29

FDA Accepts Biologics License Application for Summit Therapeutics' Ivonescimab in EGFR-Mutated NSCLC

Reuters
·
Jan 29

Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (Bla) Seeking Approval for Ivonescimab in Combination With Chemotherapy in Treatment of Patients With Egfrm Nsclc Post-Tki Therapy

THOMSON REUTERS
·
Jan 29

Summit Therapeutics Inc: Pdufa Goal Action Date of November 14, 2026

THOMSON REUTERS
·
Jan 29

BUZZ-Guggenheim initiates coverage on Crescent Biopharma with 'buy'

Reuters
·
Jan 21

Trip.com, Regencell Bioscience, And Atlassian Are Among Top 10 Large Cap Losers Last Week (Jan. 12-Jan. 16): Are the Others in Your Portfolio?

Benzinga_recent_news
·
Jan 19

Alpha Buying: Managing Biotech Risk With Insider Clues

Benzinga_recent_news
·
Jan 16

Jefferies Reaffirms Their Buy Rating on Summit Therapeutics (SMMT)

TIPRANKS
·
Jan 15

Summit Therapeutics Files Marketing Application for Lung Cancer Therapy

MT Newswires Live
·
Jan 12

Summit Therapeutics and GSK Partner to Evaluate Ivonescimab and B7-H3 ADC in Solid Tumors

Reuters
·
Jan 12

Summit Therapeutics Inc - to Supply Ivonescimab, GSK to Manage Clinical Operations

THOMSON REUTERS
·
Jan 12

Summit Therapeutics Announces Clinical Trial Collaboration With GSK to Evaluate Ivonescimab in Combination With GSK’s B7-H3 Antibody Drug Conjugate (ADC)

THOMSON REUTERS
·
Jan 12